DrugBaron

FEBRUARY 7, 2022

Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. We are most familiar with the numbers involved when dealing with antibodies: a typical antibody library might contain 10 13 different clones – but even that hardly scratches the surface of the 10 80 or so possible CDR sequences.

Small Molecule 100

Small Molecule Synthetic Chemistry Pharma Companies Pharmacokinetics 100

Drug Channels

FEBRUARY 11, 2022

Today’s guest post comes from John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds. John discusses some of the findings in CoverMyMeds’ recently published report on medication access. He describes patient-centric, data-driven solutions to help patients access, afford, and adhere to their therapies. To learn more, download CoverMyMeds’ 2022 Medication Access Report.

Therapies 98

Therapies Drugs 98

Drug Discovery Today

FEBRUARY 10, 2022

The topic of this month’s newsletter from Drug Discovery Today is “PROTACS”.

Drugs 113

Drugs 113

ProRelix Research

FEBRUARY 8, 2022

A lot has changed over the past few decades in the way clinical trials are conducted. Advances in data management systems, risk-based monitoring, pharmacovigilance, electronic databases, and application of complex […]. The post Clinical Trial Outsourcing and Management in USA appeared first on ProRelix Research.

Clinical Trials 86

Clinical Trials Trials Research Regulations 86

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Sygnature Discovery

FEBRUARY 11, 2022

We’re thrilled to be working with cutting-edge new Dutch biotech company River BioMedics to identify new drugs that directly treat heart failure and cardiovascular disease – the number one cause of death in the world. This exciting partnership combines our novel assay development and hit identification expertise with River BioMedics unique, state-of-the-art technology: advanced human-predictive in vitro 3D heart models, plus their deep knowledge of cardiac biology.

Assay Development 52

Assay Development Engineering Disease Science 52

Drug Channels

FEBRUARY 7, 2022

Drug Pricing Transparency Congress. Hybrid Event March 28-29, 2022 | Philadelphia, PA www.informaconnect.com/drug-pricing-transparency. Don’t miss the Drug Pricing Transparency Congress on March 28-29, 2022! You'll be part of the important discussions on how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices.

Drugs 97

Drugs Compliance International Regulations 97

Policy Prescription

FEBRUARY 9, 2022

Mark Cuban’s new online pharmacy venture – the Mark Cuban Cost Plus Drug Company (“Cost Plus Drug”) – will not help overcome the biggest obstacle to drug affordability in America, which is drug company monopolies on patented brand name prescription drugs. When only one company makes a drug and can charge as much as the market will bear, which is the case in the United States, the prices are often outrageous, with several treatments exceeding half a million dollars.

Pharmacy 52

Pharmacy Online Pharmacies Pharmaceuticals FDA Approval 52

The Pharma Data

FEBRUARY 11, 2022

Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019. Over the last 50 years, Sanofi has grown into a diverse, global healthcare leader, with a rich heritage of patient-centric scientific discovery. This history includes the first treatments for many rare diseases and the establishment of standards of care in diabetes and cardiovascular disease.

Vaccine 52

Vaccine Science Treatment Disease 52

Drug Channels

FEBRUARY 8, 2022

More than four years ago, I warned about the emerging trend of copay accumulators and outlined the costly consequences for patients. The latest data reveal that copay accumulator adjustment programs are now in the word list for a growing share of pharmacy benefit designs. What’s more, adoption of copay maximizers now exceeds that of copay accumulators.

Pharmacy 98

Pharmacy Drugs 98

Drug Patent Watch

FEBRUARY 10, 2022

Annual Drug Patent Expirations for BARHEMSYS Barhemsys is a drug marketed by Acacia and is included in one NDA. There are four patents protecting this drug. This drug has thirty-eight…. The post New patent for Acacia drug BARHEMSYS appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug & Device Law

FEBRUARY 11, 2022

Today’s case isn’t drug/device, but it’s something our defense-oriented readers should know about. At the tail end of 2021, the Pennsylvania Commonwealth Court laid this rotten egg: Commonwealth v. Monsanto Co. , A.3d , 2021 WL 6139209 (Pa. Cmwlth. Dec. 30, 2021) (“ CvM ”). The Commonwealth Court is a unique Pennsylvania judicial body, mostly devoted to hearing appeals from state governmental bodies, however, it does have original (as opposed to appellate) jurisdiction over certain matters br

Government 72

Government Production Compliance Marketing 72

Drug Patent Watch

FEBRUARY 10, 2022

Annual Drug Patent Expirations for STRIBILD Stribild is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Gilead Sciences drug STRIBILD appeared first on DrugPatentWatch - Make Better Decisions.

Science 52

Science Drugs Marketing 52

Drug Patent Watch

FEBRUARY 10, 2022

Annual Drug Patent Expirations for GENVOYA Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are thirteen…. The post New patent for Gilead Sciences drug GENVOYA appeared first on DrugPatentWatch - Make Better Decisions.

Science 52

Science Drugs Marketing 52

Drug Patent Watch

FEBRUARY 10, 2022

Annual Drug Patent Expirations for APRETUDE Apretude is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. The generic ingredient in…. The post New patent for Viiv Hlthcare drug APRETUDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

FEBRUARY 9, 2022

Annual Drug Patent Expirations for OPZELURA Opzelura is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are ten patents…. The post New patent for Incyte Corp drug OPZELURA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

FEBRUARY 9, 2022

Annual Drug Patent Expirations for EPANED Epaned is a drug marketed by Azurity and Silvergate Pharms and is included in two NDAs. It is available from one supplier. There are…. The post New patent for Azurity drug EPANED appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

FEBRUARY 8, 2022

Annual Drug Patent Expirations for DESCOVY Descovy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are six…. The post New patent for Gilead Sciences drug DESCOVY appeared first on DrugPatentWatch - Make Better Decisions.

Science 52

Science Drugs Marketing 52

Drug Patent Watch

FEBRUARY 8, 2022

Annual Drug Patent Expirations for CAPLYTA Caplyta is a drug marketed by Intra-cellular and is included in one NDA. There are eleven patents protecting this drug. CAPLYTA drug price trends.…. The post New patent for Intra-cellular drug CAPLYTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

FEBRUARY 7, 2022

Annual Drug Patent Expirations for UKONIQ Ukoniq is a drug marketed by Tg Theraps and is included in one NDA. There are seven patents protecting this drug. This drug has…. The post New patent for Tg Theraps drug UKONIQ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

FEBRUARY 5, 2022

Annual Drug Patent Expirations for SELZENTRY Selzentry is a drug marketed by Viiv Hlthcare and is included in two NDAs. It is available from one supplier. There are three patents…. The post New patent expiration for Viiv Hlthcare drug SELZENTRY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

FEBRUARY 5, 2022

Annual Drug Patent Expirations for CAPRELSA Caprelsa is a drug marketed by Genzyme Corp and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent expiration for Genzyme Corp drug CAPRELSA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

FEBRUARY 6, 2022

SYMBICORT (budesonide; formoterol fumarate dihydrate) Astrazeneca Patent: 7,967,011 Expiration: Feb 11, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…. The post Drug Patent Expirations for the Week of February 6, 2022 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Pharmaceuticals 40

Drug Patent Watch

FEBRUARY 5, 2022

SYMBICORT (budesonide; formoterol fumarate dihydrate) Astrazeneca Patent: 7,967,011 Expiration: Feb 11, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…. The post Drug Patent Expirations for the Week of February 6, 2022 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Pharmaceuticals 40

Drug Patent Watch

FEBRUARY 5, 2022

This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Drugs 98

Drug Patent Watch

FEBRUARY 11, 2022

This chart shows the drugs with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

FEBRUARY 10, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Germany. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Germany? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

FEBRUARY 9, 2022

This chart shows the patent expirations for capsule dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Capsule dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs 52

Drug Patent Watch

FEBRUARY 8, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Estonia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Estonia? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Patent Watch

FEBRUARY 7, 2022

This chart shows the pharmaceutical companies with the most concentrate dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most concentrate dosed drugs…. The post Which pharmaceutical companies have the most concentrate dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

FEBRUARY 6, 2022

This chart shows the drugs with the most patents in Ireland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug & Device Law

FEBRUARY 9, 2022

Don’t stop us if you’ve heard this before, because we know you have. Plaintiffs cannot compel hospitals to treat Covid-19 patients with ivermectin. A Florida appellate court recently joined courts in Delaware (we wrote about the Delaware case here ), Michigan ( here ), New York ( here ), and Texas ( here ) in rejecting an injunction that would have forced a hospital to treat a Covid-19 patient with an ivermectin cocktail.

Doctors 64

Doctors Hospitals Testimonials Treatment 64

Drug & Device Law

FEBRUARY 10, 2022

A federal court applying Florida law has refused to dismiss fraud and misrepresentation claims brought by a patient against a medical-device manufacturer, rejecting the manufacturer’s contention that such claims are categorically barred by the learned-intermediary doctrine. It is perhaps telling that the decision, Pirlein v. Ethicon, Inc., Med. Devices Rep. ¶ 24,799 (S.D.

Doctors 52

Doctors FDA Treatment 52

Drug & Device Law

FEBRUARY 7, 2022

MDL defendants in prescription medical product liability MDLs have been complaining for years about thousands of cases being brought without the slightest pre-filing vetting – “plaintiffs” who cannot establish that they ever actually used the products of the defendant(s) they have sued and/or who similarly have no proof that they suffered the injury(ies) as to which the MDL was created.

Production 59

Production Trials Marketing 59

Drug & Device Law

FEBRUARY 8, 2022

Today’s post is not about something cutting edge or controversial. It’s a don’t lose sight of the basics kind of post. Plaintiff bears the burden of proof on causation. In a prescription drug failure to warn case, that means plaintiff must demonstrate that a different warning would have changed whether the drug would have been prescribed to plaintiff or, in some circumstances, prescribed in the same way.

Testimonials 59

Testimonials Drugs 59